1. Abbreviations used in thispaper: GP, glycoprotein; PCR, polymerase chain reaction; PRP, platelet-rich plasma; VNR, vitronectin receptor.
Introduction
The platelet fibrinogen receptor is composed of a complex of glycoproteins (GP) Ilb and IIIa on the surface of platelets. Deficient function of this receptor prevents normal platelet aggregation, resulting in Glanzmann's thrombasthenia (GT). In this paper, we describe a black thrombasthenic patient who is either homozygous or hemizygous for a deletion within the GPIIb gene. Initial Western blot analysis of platelet proteins from this patient did not detect any GPIIb, but did detect small amounts of GPIIIa of normal mobility. Quantitation of vitronectin receptor (VNR) demonstrated that this thrombasthenic patient had -1.5-2 times the number of these receptors per platelet compared with controls, a finding that has previously been noted in other thrombasthenic patients with defects in GPIIb. Genomic Southern blot studies demonstrated a deletion in the GPIIb gene of -4.5 kilobasepairs (kb). Analysis of the isolated GPIIb gene demonstrated that the deletion begins between two Alu repeats within intron 1 and ends in intron 9. Polymerase chain reaction (PCR) studies using platelet RNA and oligonucleotides directed to both the 5' and 3' ends of the GPIIb cDNA sequence easily detected GPIIb transcript, suggesting that the genomic deletion of exons 2-9 does not significantly decrease the level of the GPIIb mRNA. Sequence analysis of PCR-generated GPIIb cDNA showed that a cryptic AG splice acceptor sequence was being utilized, resulting in a transcript that contained a portion of introns 1 and 9, as well as having a deletion of exons 2-9. Unlike the GPIIb gene, the GPIIIa gene appears to be intact by Southern blot analysis. PCR studies using platelet RNA and oligonucleotides directed to the GPIIIa cDNA sequence demonstrated the presence of GPIIIa mRNA. In summary, the thrombasthenic state in this patient appears to be due to a GPIIb gene deletion resulting in an abnormal transcript and no detectable platelet GPIIb. Platelet GPIIIa levels were secondarily low presumably due to the known instability of GPIIIa in the absence of GPIIb. (J. Clin Receivedfor publication 14 May 1990 and in revisedform 24 July 1990.
The major fibrinogen receptor on the surface ofactivated platelets is a calcium-dependent heterodimeric complex of(GPIIb)' glycoprotein Ilb and GPIIIa (1) (2) (3) (4) . This receptor contains binding sites for von Willebrand factor, fibronectin, and vitronectin as well as fibrinogen (2) (3) (4) (5) (6) (7) . The cDNAs for near full-length GPIIb and GPIIIa have been cloned, and the encoded primary amino acid sequences deduced (8) (9) (10) (11) (12) . Northern blot analysis of RNA from various tissues as well as immunologic and related studies have demonstrated that GPIIb is normally expressed only in platelets, whereas GPIIIa is also present on other tissues, where it is complexed with the av subunit to form the vitronectin receptor (av#3) (VNR) (13) (14) (15) (16) . It is interesting that gene localization studies with the GPIIb and GPIIIa cDNAs have demonstrated that these genes are within 250 kilobasepairs (kb) of each other on the long arm of chromosome 17 (17) . Whether this unusual proximity for two concurrently expressed genes is related to their expression in platelets is not presently known.
The GPIIb/IIIa complex is one of the integrins, a family of heterodimeric receptors that are involved in cell-cell and cellmatrix interactions (15, 16) . Many ofthese receptors bind to an overlapping group of extracellular adhesion proteins, and this binding can often be competitively inhibited by Arg-Gly-Aspcontaining synthetic peptides (7, (18) (19) (20) (21) . A number of unique a (GPIIb-like) chains complex with a smaller number of more ubiquitous ( (GPIIIa-like) chains to form these receptors. Sequence analysis of the cDNAs for a number of the a chains have been published, and the encoded proteins share -30-70% amino acid identity (9, (22) (23) (24) (25) (26) (27) (28) (29) . The mature a chains are 140 kD and many ofthese a chains consists oftwo disulfidelinked subchains. In an analogous fashion, sequence analysis of the cDNAs of a number of the #3 chains has also been accomplished, and the encoded proteins also share amino acid homology (10, 11, (30) (31) (32) . The ,3 proteins are single chains of -95 kD, and contain four cysteine-rich domains. Unlike the close proximity of GPIIb and GPIIIa on chromosome 17, the genes for other a and # chains are fairly well distributed within the human genome (12, 33, 34) .
Glanzmann's thrombasthenia is a rare autosomal recessive bleeding disorder in which platelets fail to aggregate during hemostasis secondary to disorders affecting the GPIIb/IIIa receptor (35) (36) (37) (38) (39) . Patients may have a qualitative and/or a quantitative defect in their GPIIb/IIIa receptor. In most of these patients, the levels of GPIIb and Ila are coordinately decreased. It is unknown if this coordinate reduction of GPI~b and GPIIIa results from decreased protein stability of nonduplexed GPIIb or GPIIIa as demonstrated in transient expression studies when the cells are transfected with only one of the two expression vectors (40) , or is due to coordinate regulation of expression of these two physically close genes (12) . The specific molecular basis of the various thrombasthenic phenotypes has yet to be elucidated. Molecular studies ofthese patients may correlate with clinical differences between those with defects in GPIIb and those with defects in GPIIIa. Also, these studies may reveal the biological significance of the close association of these two genes on chromosome 17. In this paper, we describe a black patient with severe Glanzmann's thrombasthenia whose bleeding diathesis appears to be secondary to a deletion within the gene for GPIIb.
Methods
Clinical history. The patient is an adopted black teenage male (K.W.) with type I Glanzmann's thrombasthenia. The initial diagnosis was established by absence of platelet aggregation after stimulation with epinephrine, collagen, and ADP. Clinically, he has moderate bleeding manifested by moderate to severe epistaxis and gingival bleeding, but requires only rare platelet transfusions. The other subjects shown in Polyclonal and monoclonal antibodies. Polyclonal antiserum specific for human platelet GPIIla was raised by immunizing rabbits with a mixture of nonreduced and reduced GPIIIa that had been affinity purified by AP3-Sepharose chromatography (41) . The anti-GPIIIa antibodies were affinity-purified from the antiserum on immobilized GPIIIa, and specificity was verified by immunoprecipitation and immonoclonal antibody PMI-l, specific for GPIIb (42) , was kindly provided by Dr. Mark Ginsberg, Scripps Institute, La Jolla, CA. Murine monoclonal antibodies LM 609 and LM 142, specific for the VNR complex and VNR a-subunit, respectively, (43, 44) were a generous gift of Dr. David Cheresh, Scripps Institute, La Jolla, CA. The affinitypurified polyclonal rabbit antibody for PECAM-I has been previously described (45) .
Platelet membrane glycoprotein analysis. Platelets from both normal control individuals and thrombasthenic K.W. were prepared by differential centrifugation of acid citrate dextrose (ACD) anticoagulated whole blood as previously described (46) . Platelets were washed three times in modified Tyrodes buffer, pH 6.8, and then lysed in a solution of 2% (wt/vol) SDS, 5% (vol/vol) fi-mercaptoethanol, and 50 mM Tris, pH 6.8. 75 ug of total protein per lane was electrophoresed through a 9% (wt/vol) SDS polyacrylamide gel, and the proteins transferred to an Immobilon (polyvinylidene difluoride) membrane (Millipore Continental Water Systems, Bedford, MA) for subsequent Western blot analysis. The GPIIb and GPIIIa content ofeach platelet lysate was determined simultaneously on the same blot by coincubation of the membranes with the anti-GPIIb murine monoclonal antibody PMI-l and the rabbit anti-GPIIIa polyclonal antibody. Equal protein loading ofsamples was assessed by coincubation ofthe blots with affinity-purified antibody specific for PECAM-1, the levels of which are unaffected by the thrombasthenic phenotype (unpublished observation). Primary antibody binding was detected using a mixture of alkaline phosphatase-conjugated goat anti-rabbit and goat anti-mouse IgGs in conjunction with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolim salt substrate pair.
Platelet VNR quantitation. Blood from the patient and two controls was drawn and anticoagulated with ACD formula A (ACD-A; 1.5 ml for 8.5 ml blood) in Milwaukee, and then coded and shipped overnight to Stony Brook. Blood from an additional control was obtained in Stony Brook immediately after the samples arrived. The platelet counts in the samples were increased by preparing platelet-rich plasma (PRP), adding 0. 1 vol of ACD-A to the PRP, centrifuging the PRP to pellet the platelets (-16,000 g min at 220C), removing some ofthe supernatant plasma, and then resuspending the pellets to achieve platelet counts of -2 x 109/ml. Antibody LM 142, directed against the VNR a, subunit, and antibody LM 609, directed against the VNR complex (af3), were purified by protein G affinity chromatography and radiolabeled with 125I using immobilized lodogen (Pierce Chemical Co., Rockford, IL). Aliquots (0.2 ml) ofthe concentrated PRP were incubated with 5,ul of buffer (0.15 M NaCl, 0.01 M Tris HCI, pH 7.4) for 30 min and then with one of the radiolabeled antibodies for 90 min at 220C. Plateletbound antibody was then separated from free antibody by centrifugation through 30% sucrose. Nonspecific binding was determined by substituting ascites fluid containing the appropriate antibody for the 541 of buffer in the first incubation step. Two different concentrations ofeach antibody were used: -110 ng/ml (range, 108-113 ng/ml) and -313 ng/ml (range, 305-321 ng/ml) for LM 142, and -129 ng/ml (range, 112-147 ng/ml) and -396 ng/ml (range, 388-405) for LM 609. Previous studies indicated that the Kd for LM 142 is -85 ng/ml, and the KS for LM 609 is -109 ng/ml; at concentrations -10 times the Kd, the mean (±SD) number of LM 142 molecules that bound to normal platelets was 22±6 (n = 10), and the number of LM 609 molecules that bound was 33±11.
Southern blot analysis. DNA was prepared from whole blood as previously described (47) . A 20-,ug aliquot was digested at 370C with 30-50 U of each restriction endonuclease using buffers and conditions recommended by the suppliers. Fragments were separated by electrophoresis through 0.6% agarose and transferred to Gene Screen Plus membrane (New England Nuclear, Boston, MA). Hybridizations and washing were carried out at 650C according to standard conditions suggested by the manufacturer. A 3.3-kb full-length GPIIb cDNA (9) , and the 5' and 3' Eco RI fragments ofthe GPIIIa cDNA (11) , comprising the full-length cDNA, were used as probes for the initial genomic Southern blot analyses. A 2.4-kb Bam HI/Bgl II GPIIb genomic fragment, containing exons 5-12 ( Fig. 2 C) (48), was used as a probe to further localize the deletion on genomic Southern blot analysis. Probes were radiolabeled with a-32P dCTP using random oligo primers and Klenow as described previously (49) .
Construction and screening ofthe thrombasthenic genomic library. Using 110 Mg of genomic DNA isolated from the thrombasthenic patient, a lambda genomic library was constructed (50) . The DNA was partially digested with Sau IIIa. Fragments from 15 to 24 kb in length were selected on a sucrose gradient, ligated to EMBL 3A arms, and packaged using the Gigapack Plus Cloning System (Stratagene, La Jolla, CA), and the resultant phage were used to infect NM539 bacteria. Screening of the library with radiolabeled GPIIb cDNA was as previously described (49) .
Characterizing the deletional breakpoint. Positive clones were plaque-purified, and the inserts were characterized by restriction analysis and Southern blotting studies using radiolabeled GPIIb cDNA probe. An Sst I restriction fragment which was anticipated to contain the deletional breakpoint was isolated and subcloned into M 13 mp 18 phage. Clones containing the insert in complementary orientations were identified using an S I nuclease protection assay (51) . In addition, Sl nuclease protection assays were performed between these singlestranded clones and the complementary normal 4.8-kb Bam HI fragment that contains exons 5-13 ( Fig. 2 C) (51) to localize the deletional breakpoint within the Sst I fragment.
Sequence analysis was performed using the Sanger method (52) and the Sequenase enzyme protocol (United States Biochemical Corp., Cleveland, OH). The antisense 15 nucleotide oligonucleotide (TGC-AGGAACAATAC) used as a primer for sequence analysis across the deletional breakpoint is complementary to bases 1108-1122 ofthe fulllength GPIIb cDNA and is located within exon 12 (48).
Platelet mRNA studies. Total cellular RNA was prepared from human platelets, and specific regions of mRNA were reverse transcribed into cDNA and then amplified using the polymerase chain reaction (PCR) technique as previously described (46, 53) . Oligonucleotide primers were used at final concentrations of 200-500 nM except for reaction tubes containing more than one primer pair (multiplex PCR), Glanzmann's Thrombasthenia with a Deletion in the Genefor Glycoprotein JIb 271 in whicti all primer concentrations were limited to 100 nM to avoid artifacts associated with primer complementarity. PCR primers 1-4 correspond to sequences of GPIIb cDNA (9), whereas primers 5 and 6 correspond to sequences of GPIIIa cDNA (10) . Following amplification, PCR reactions products were resolved on GTG agarose gels (FMC Corp., Rockland, ME) recovered using GENECLEAN (Bio 101 Co., La Jolla, CA), and sequenced directly using T7 DNA polymerase (Sequenasetm; United States Biochemical Corp., Cleveland, OH) according to manufacturer's recommendations. In some instances cDNA fragments were blunt-end ligated into the Eco RV-cut plasmid vector pGEM-5Zf for restriction site and DNA sequence analyses.
Oligonucleotides used for these studies include the GPIIb oligonucleotides I (GGCCAGAGCTTGTGTCCACTCTGC) for GPIIb, bases 4-26 (sense), 2 (CCATATACAGTGGAGCGCCCACC) for GPIIb, bases 1037-1015 (antisense), 3 (GAGCTGCAGATGGACGCAGCC-AAC) for GPIIb, bases 1988-2011 (sense), 4 (CAGGAAGGCCAG-CACCGTGACCATG) for GPIIb, bases 2821-2797 (antisense), 5 (CATGTGTGCCTGGTGCTCTGATG) for GPIlIa, bases 161-183, and 6 (CACCTGGTCAGTTAGCGTCAGCAC) for GPIlIa, bases 698-674 (antisense). These primers are schematically shown at the top of Fig. 4 .
Results
Immunoblot analysis ofGPIIb and GPIIIa. The thrombasthenic phenotype of patient K.W. was confirmed by immunoblot analysis using a mixture of anti-GPIIb, anti-GPIIIa and anti-PECAM-1 antibodies. As shown in Fig. 1 , K.W. had undetectable levels of GPIIb. Significantly, GPIIIa was present at approximately 1-5% ofnormal levels, and that which was present comigrated with normal GPIIIa. That approximately equal amounts ofprotein were loaded in each lane was demonstrated by immunostaining with anti-PECAM-1, which is known to be present in normal amounts in thrombasthenic platelets (Newman, P.J., unpublished observations), consistent with a primary defect in GPIIb, with GPIIIa levels being secondarily affected.
Platelet VNR quantitation. The results of the antibody LM 142 and LM 609 binding studies are presented in Table I . The values for the control samples drawn in Milwaukee were similar to those of the fresh sample drawn in Stony Brook, suggesting that the lag time involved in transporting the samples did not significantly affect the results. The values for the higher g E .I doses of antibody binding to control platelets were also similar to the values previously obtained using near-saturated concentrations of the antibodies with other normals drawn fresh at Stony Brook (LM 142 = 22±6 molecules per platelet, and LM 609 = 33±1 1 molecules per platelet).
Each of the values for the patient's platelet exceeded the highest value for any of the controls; the increases in binding for both antibodies were concordant (LM 142, -180% control; LM 609, 200%). These results indicate that at least some of the GPIIIa identified by immunoblot analysis is associated with the av, subunits to form VNR. Since this indicates that the patient's GPIIIa is able to complex with an a subunit normally, it suggests that the patient's defect would be in the GPIIb unit. Analysis of other patients with thrombasthenia have shown that in those patients with a GPIIb defect, that the number of anti-VNR antibody bound per platelet is similarly increased in patients whose defects are in GPIIb (54-56).
Southern blot analysis ofthe genes for GPIIb and GPIIIa. Southern blot analyses ofgenomic DNA from patient K.W., a normal control, and two additional thrombasthenic patients were performed using restriction endonucleases Hind III, Sst I, and Bam HI, and compared with blots of a panel of normal controls. Blots hybridized with radiolabeled full-length GPIIIa cDNA demonstrated completely normal banding patterns in all four patients (data not shown). The identical blots were also hybridized with radiolabeled full-length GPIIb cDNA (Fig. 2, A and B). The normal control and the two other thrombasthenic patients demonstrated the anticipated restriction pattern. However, patient K.W. had an absence of a 13.9-kb Hind III fragment with the appearance of a new 9.4-kb fragment (Fig. 2 B) , an absence of a 9.6-kb Sst I fragment with the appearance of a new 5.0-kb fragment (Fig. 2 A) , and an absence ofa 4.8-kb Bam HI fragment (data not shown). These findings are consistent with a homozygous or hemizygous 4.5-5.0-kb deletion encompassing a major portion ofthe coding regions ofthe absent Bam HI fragment and localizes the deletion to a region beginning downstream of exon 1 at its 5' end and the exon 13-18 cluster at its 3' end in Fig. 2 B. Further localization ofthe deletion was accomplished by hybridizing the same Hind III/Bam HI blot to radiolabeled 2.4-kb Bam HI/BgI II genomic GPIIb fragment (which includes exon 5-12 in Fig. 2 B) . Results of this experiment (data not shown) revealed that the large 9.4-kb Hind III fragment is present, and the 4.8-kb Bam HI fragment is absent. A new 9.8-kb Bam HI fragment was now detected that was not appreciated with the GPIIb cDNA probe. This new band must result from a deletion of the Bam HI site near exon 5, and further localizes the deletion to within a region that extends downstream of exon I to near exon 12 in Fig. 2 C. In order to define the deletion endpoints a partial Sau II1a genomic library of the patient's DNA was constructed and screened. Three positive clones were isolated after screening a total of 400,000 plaques with the full-length GPIIb cDNA probe. Restriction analysis demonstrated that all three clones included a 5.3-kb Sst I fragment. This fragment would be expected to encompass the deleted area, and represents a 4.6-kb shortening of the normal Sst I fragment shown in Fig. 2 B. Initial localization of the deletional breakpoint was done using an S1 nuclease protection assay between single-stranded Ml 3 phage containing the patient's truncated Sst I fragment and single-stranded Ml 3 phage containing the normal 4.8-kb Bam HI genomic fragment which contains exons S through 13 in Fig. 2 C. A fragment of -3.3 kb was protected, placing the 3' deletion breakpoint within the cluster of exons 8-12 (data not shown).
Sequence analysis across the deletional breakpoint was accomplished using single-stranded DNA of the 5.3-kb Sst I thrombasthenic insert in M1 3 mpl 8 phage as template and a complementary antisense oligonucleotide to a region of exon 12 (48) as primer as described in Methods. The upstream breakpoint of the deletion is in intron 1, and is 483 bp 3' to exon 1 and is within the 5' end of the second of a pair of direct Figure 3 . Sequence analysis of deletion breakpoint. Sequence analysis ofthe interval between exon I and exon 10 ofGPIIb in K.W. Exons are indicated as open boxes. Sequence 5' to the deletion and corresponding to normal intron I is shown in small letters, while those 3' to the deletion and corresponding to normal intron 9 is shown as capital letters. Between these two sequences is a short region of 10 bases that does not correspond to either and is boxed with a dashed line. The site of a difference in the length of a poly A stretch (20 in normal and 11 in K.W.) is indicated by an asterisk. The cryptic splice acceptor site is circled and splices in K.W. to the normal splice site preceding exon 10 (see Results). The resulting in-frame TAA termination codon is dot overlined.
Alu repeats (57) (Fig. 3 ). The only difference between the published normal sequence and K.W.'s in this region is the length of the poly A region at the end of the Alu repeat, which is 20 in the normal and 11 in K.W. (asterisk in Fig. 3) . This difference may represent a polymorphism. At the 3' end, the deletion ends in intron 9, and is 69 bp Yto the start ofexon 10, and 1551 bp 5' to an Alu repeat in intron 12 (48). Between the two breakpoints is an additional 10 bp that has only limited homology with either the normal 5' or 3' GPIIb sequence (dash-boxed in Fig.   3 ). The deletion includes 2.0 kb of intron 1 that has yet to be sequenced (48), so that the exact size of the deletion is not known but is estimated to be 4.5 kb. PCR analysis ofnormal and K. W. platelet RNA transcripts.
To assess the effect on transcription and mRNA processing of this major deletion in the GPIlb gene, we initially attempted without success to analyze platelet GPIIb and GPIIIa mRNA by Northern blot analysis (data not shown). Platelets contain only small amounts of residual RNA, and the inability to demonstrate the presence of GPIIb and GPIIIa RNA might simply reflect this technical problem in obtaining sufficient RNA. We, therefore, used the more sensitive approach of reverse transcribing the RNA into single-stranded complementary DNA followed by PCR amplification (46, 53) . This approach allowed us to analyze whether there is detectable GPIIb mRNA in K.W.'s platelets and to study the effect ofthe genomic deletion on intron processing. Several primer pairs, delineated in Methods, were used. The results of studies with normal and K.W.'s total platelet RNA using the two primer pairs for GPIIb mRNA and the one pair for GPIIIa that are schematically illustrated at the top of Fig. 4 are discussed below.
Primer pairs 3 + 4 normally result in an amplified DNA segment of 833 bp and 5 + 6 normally result in an amplified DNA segment of 537 bp. PCR analysis ofthe patient's platelet RNA with both of these oligonucleotides demonstrate that both GPIIb and GPIIIa mRNAs are detectable in K.W.'s platelet RNA with the same size and quantity of final PCR product as in the normal control ( Fig. 4 A) cated from the genomic cloning experiments, with primer 1 4 located within exon 1 of the GPIIb gene, and primer 2 corre-3_ sponding to a region on the antisense strand within exon 12.
The PCR product expected from this primer pair is 1,033 bp, and this band is observed in studies with normal platelet RNA ( Fig. 4 A) . In light of the fact that exons 2-9 are deleted in the genome of K.W., we expected a 296-bp PCR product using *lb1033 K.W.'s platelet RNA as starting material, assuming that exon 1 *llb 580 spliced to the next normal splice acceptor site which is found preceding exon 10. Unexpectedly, the PCR product obtained was 580 bp. Sequence analysis demonstrated that this 580-bp cDNA band encoded parts of intron 1 and 9, consistent with the utilization of a cryptic AG splice acceptor located within a iPu1b Primers pyrimidine-rich region of intron 1 (48) (circled in Figs. 3 and 4 Plila Primers B). This splice acceptor site probably becomes exposed due to secondary structure modifications in the heteronuclear GPIIb B
RNA transcribed from the deleted GPIIb gene. Thus a pseudoexon is formed that contains a portion of introns 1 and 9 as well as all ofexon 10 ( Fig. 4 B) . The resulting GPIIb mRNA has an in-frame TAA termination codon 26 triplets downstream etc. }e-L from the end of exon 1 (dot overlined in Fig. 3 shown as a heavier black line and intron 9 is shown as a heavier grey line. The cryptic splice acceptor site is indicated as an encircled AG. The breakpoints ofdeletion are indicated by the break in the introns bordered by two short diagonally placed lines, and the actual DNA sequence deleted is shown under a diagonally shadowed region.
Below is a schematic representation of the GPIlb gene in K.W. in this same region, and beneath this is a schematic representation of the initial RNA transcript of this partially deleted gene in the region of interest, with the breakpoint point of the deletion indicated. At the Although previous studies suggest that Glanzmann's thrombasthenia is due to a heterogeneous group ofdefects, the molecular basis for this heterogeneity has only begun to be defined on a molecular level. It is very likely that this disease will prove to be heterogeneous with many different mutations being defined in different ethnic groups and in patients with different clinical severity much as has already been demonstrated with the thalassemias (58) . The classical division into the two categories of severely GPIIb/IIIa-deficient patients (type I) and those less deficient (type II) will be replaced by a precise definition of defects and correlation with phenotype. Recently, a patient heterozygous for an insertion in the GPIIIa gene has been reported (59) . In this report, we describe a black thrombasthenic patient homozygous or hemizygous for a 4.5-kb deletion in the 5' region of the GPIIb gene. This deletion eliminates exons 2-9. Because natural relatives of this adopted subject are not available, further family studies could not be done to distinguish between the two possibilities. As noted previously, the GPIIb gene is rich in Alu repeats, having at least 10 repeats distributed throughout its 17-kb sequence (48). All of these repeats are oriented in the same direction. At its 5' end, the deletion in K.W. occurs within a direct Alu repeat. However, most deletions for which the end-points ofthe breakpoint have been defined (e.g., the thalassemias [58] ) do not involve Alu repeats. The fact that only one end of this patient's deletion occurs within a direct Alu repeat suggests that a nonhomologous crossover involving Alu repeats could not have caused this patient's deletion.
The large deletion in the GPIIb gene in K.W. results in an abnormal transcript that is missing exons 2-9, but contains bottom is a schematic representation of the final mature GPIIb RNA. This mRNA has exon 1, a portion ofintrons I and 9, and exons 10-30. portions of introns I and 9. This RNA is processed in the nucleus, using the normal exon I splice donor and a cryptic splice acceptor site in intron 1 to form a GPIIb mRNA species that is missing exons 2-9 and portions of introns 1 and 9 as well as exon 1 and exons 10-30. This mRNA species is sufficiently stable as to yield PCR-amplifiable GPIIb cDNA fragment from platelet total RNA. Unfortunately, while the amount of total RNA that can be isolated from platelets is sufficient for demonstrating a qualitative defect in K.W.'s GPIIb mRNA, it is insufficient to quantitate the relative level of his GPIIb mRNA beyond stating that this mRNA species was present in platelets in sufficient amounts to be detectable by PCR amplification.
In contrast to the GPIIb gene in this patient, the GPIIIa gene appears intact. Within the limitations of restriction endonuclease mapping of genomic DNA, the GPIIIa gene does not appear to have a deletion or rearrangement. Transcription from this gene has been shown by PCR analysis for GPIIIa using the patient's platelet RNA. This mRNA is translated into GPIIIa with normal mobility as demonstrated on Western blot analysis. However, the level of this platelet GPIIIa protein is only 1-5% of normal. This low level of GPIIIa expression is most likely due to instability of unduplexed GPIIIa as shown by both pulse-chase studies of human megakaryocytes and megakaryocyte-like cell-lines (40) , and by transient expression studies of recombinant GPIIb and MIla in COS cells where transfection of either GPIIb or i11a alone did not result in any surface expression, while cotransfection studies resulted in completion of GPIIb maturation and the expression of the GPIIb/IIIa complex on the cell surface (60) . A small portion of platelet GPIIIa protein does form stable duplexes with VNRa (61, 62) . As in other patients with a deficiency in GPIIb, newly synthesized GPIIIa complexes with the small internal pool of VNRa chains, resulting in an increased level of VNR on the platelet surface, rescuing the 1-5% of GPIIIa molecules observed in such platelets. To explain why patients with defects in GPIIb may have an increase in platelet VNR, one can postulate that GPIIb and VNRa normally compete for a pool of GPIIIa molecules, and those GPIIb and VNRa molecules that fail to complex with a GPIIIa molecule are proteolytically digested. If GPIIb synthesis is impaired, then there will be fewer GPIIb molecules to compete for GPIIIa, and thus it is more likely that the VNRa molecules synthesized will join with GPIIIa molecules and be transported to the platelet membrane as VNR. Thus, the small amount of GPIIIa seen on the Western blot may be due solely to the presence of GPIIIa within the platelet VNR or be due in part to residual unduplexed cytoplasmic GPIIIa.
